More than a third of patients newly diagnosed with type 2 diabetes mellitus did not receive the recommended first-line drug, a finding that could have substantial implications for healthcare spending, according to a study published in the American Journal of Medicine.
New molecular entity: FDA approved lucinactant (Surfaxin, Discovery Laboratories) for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk of RDS.
FDA recently issued a warning about an increased risk of developing new cancers for patients taking lenalidomide (Revlimid, Celgene) for the treatment of multiple myeloma.
Recent FDA Approvals (through May 2012) related to (Meda, Novo Nordisk, Janssen, Vivus, Clinigen, GlaxoSmithKline, Stride Arcolab)
Recent FDA action (through May 2012) related to, Loxapine, Adasuve, Alexza Pharmaceuticals, Denosumab, Xgeva, Amgen, Furiex, Takeda, Nesina, alogliptin, fixed-dose combination alogliptin and pioglitazone, Liovel, Emtricitabine and tenofovir disoproxil fumarate, Truvada, Gilead Sciences, Lorcaserin, Arena Pharmaceuticals, Eisai, Tofacitinib, Pfizer, Tafamidis, ACH-3102, Achillion, CK-2017357, Cytokinetics, Taliglucerase alfa, Elelyso, Pfizer, Carisbamate, SK Biopharmaceuticals, Vancomycin hydrochloride, Vancocin, Akorn, Watson
On May 15, 2012, FDA announced completion of their safety review of fingolimod (Gilenya, Novartis).
As FDA considers a new paradigm that would expand the definition of nonprescription drugs, healthcare experts say the proposed paradigm could have its benefits and challenges for the healthcare industry.
A look at liposomal bupivacaine, a local anesthetic providing pain relief post-surgery
New molecular entity: FDA approved the synthetic, pegylated erythropoiesis-stimulating agent (ESA) peginesatide (Omontys, Affymax) for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis.
The drive for personalized medicine and greater patient involvement in treatment decisions demands more informative data on the effects and risks associated with drugs and medical products.
Chronic kidney disease (CKD) remains a significant cause of morbidity and mortality. Here's a review of treatment options and guidelines to delay disease progression.
Market is expanding for government health IT contracts.
Managed care organizations need to look toward the future market in long-term care.
A survey by Express Scripts shows that patients tend to think that they are more compliant than they are.
Healthcare experts say a move away from the fee-for-service payment model can't happen too soon.
Support school nurses who can improve kids' health.
Providers, especially primary care physicians, are struggling to meet increasing demands.
Few consumers are able to find adequate cost and quality information that truly helps them make cost-conscious healthcare decisions
Sure, you need to eat right and exercise, but why aren't you doing it?
With health reform transforming the industry, a study from the Employee Benefit Research Institute (EBRI) shows the current realities of employer-based care.
Well-constructed data integration strategies can help manage the swelling data flood.
A policy requirement that employers with more than 200 full-time employees must enroll their employees in a company health plan may not take effect until 2015.
Oncology pathways can lead to quality programs and more cost-effective care for cancer patients.
Congress wants to get serious about fixing the Medicare formula for reimbursing physicians, an initiative that would affect healthcare rates and expenditures more broadly.
Providers pledge to drive out waste by avoiding certain unnecessary services, and many believe it's a good first effort at true cost control.
Program for Afib patients could provide template of improved outcomes.
Medicare Advantage's star rating program includes overly ambitious benchmarks.
The use of benzocaine gels and liquids to soothe teething and mouth and gum pain can lead to a rare but serious?and sometimes fatal?condition called methemoglobinemia, according to an FDA Consumer Update.
The drug-shortage crisis got a step closer to being alleviated Thursday, when the U.S. Senate passed FDA?s Safety and Innovation Act (SB-3187).
The use of atypical antipsychotics in patients with major depressive disorder who have not responded to antidepressant therapy substantially increased clinical response rates at 6 weeks; however the drugs are also much more costly, according to the results of an analysis published in the May issue of The Annals of Pharmacotherapy.